Industry research forecasts that AI hyperscalers will spend at least $500 billion on infrastructure in 2026.
However, Novo Nordisk has a plan to get things back on track, and the company's oral Wegovy is part of that strategy. In December, Novo Nordisk earned approval for the oral version of its famous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results